Dynarex Corporation Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Dynarex Corporation Pharmaceutical Import Records from India — 2 Products, $2.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Dynarex Corporation — Pharmaceutical Importer Profile (2026) | 2 Products, $2.8M Trade | TransData Nexus

Dynarex Corporation

Pharmaceutical Importer · United States · Vitamins & Supplements Focus · $2.8M Total Trade · DGFT Verified

Dynarex Corporation is a pharmaceutical importer based in United States with a total trade value of $2.8M across 2 products in 2 therapeutic categories. Based on 227 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Dynarex Corporation sources from 3 verified Indian suppliers, with Gopaldas Visram And Company Limited accounting for 57.3% of imports.

Dynarex Corporation — Import Portfolio & Supplier Network

Dynarex Corporation import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Dynarex Corporation?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gopaldas Visram And Company Limited	$3.3M	214	57.3%
Altova Healthcare Limited	$1.4M	234	24.6%
Gopaldas Visram Company Limited	$1.0M	85

What Formulations Does Dynarex Corporation Import?

Formulation	Value	Ships
Bacitracin ointment 0.9 g (net	$261.1K	7
Triple antibiotic ointment 0.9g (net	$212.5K	7
Rugby zinc oxide ointment 20%	$167.2K	8
Hydrocortisone cream 0.9	$159.1K	4
Bacitracin zinc ointment 15 oz (net	$148.2K	5
Bacitracin zinc ointment USP 0.9GM	$130.3K	4
Hydrocortisone cream USP	$125.1K	4
Hydrocortisone cream USP 1 oz(28.4g)	$123.1K	10
Bacitracin ointment 0.9g (bacitracin	$122.9K	5
Dynashield skin protectant barrier	$104.5K	17
Hydrocortisone cream USP 1	$101.2K	10
A&d ointment	$96.4K	7
Bacitracin ointment 0 9 g net	$92.8K	3
Zinc oxide ointment 15oz (batch no.	$84.7K	5
Bacitracin ointment USP 1 oz tube (net	$70.1K	3

Dynarex Corporation imports 313 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Zinc	Vitamins & Supplements	$2.0M	176	2.5%	10
2	Hydrocortisone	Corticosteroids	$806.4K	51	1.2%	9

Dynarex Corporation imports 2 pharmaceutical products across 2 categories into United States totaling $2.8M.

Dynarex Corporation — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Dynarex Corporation, established in 1967, is a privately held company headquartered in Montvale, New Jersey. The company specializes in manufacturing and distributing a comprehensive range of medical equipment, including durable medical equipment (DME) and disposable medical products. Their product portfolio encompasses items such as wound care supplies, incontinence care products, and laboratory essentials. Dynarex's guiding principle, "We Care Like Family," underscores its commitment to delivering quality and value to healthcare professionals, care providers, and families.

While Dynarex's primary focus is on medical equipment, their import activities indicate a strategic approach to sourcing pharmaceutical formulations from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $2.8 million USD, comprising 227 shipments. These imports included 313 unique formulations across two therapeutic categories: Vitamins & Supplements and Corticosteroids. The top five imported products were Zinc ($2.0 million, 2.5% share) and Hydrocortisone ($806,000, 1.2% share), highlighting a significant reliance on these specific formulations.

2Distribution Network

Dynarex operates a robust distribution network to ensure timely delivery of its products across the United States. The company's headquarters in Montvale, New Jersey, serves as a central hub for operations. While specific warehouse locations are not publicly disclosed, Dynarex's extensive logistics capabilities enable efficient nationwide coverage. The company emphasizes a "one-stop shopping" experience, allowing customers to source a wide array of medical supplies from a single provider.

3Industry Role

In the United States pharmaceutical supply chain, Dynarex Corporation functions primarily as a distributor and wholesaler of medical equipment and supplies. Their import activities from India suggest a strategic sourcing approach to enhance their product offerings, particularly in the pharmaceutical sector. By integrating these imported formulations into their distribution network, Dynarex aims to provide comprehensive solutions to healthcare providers and consumers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Dynarex Corporation

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Dynarex's sourcing strategy from India reveals a high degree of supplier concentration. The company has engaged with three unique Indian suppliers:

GOPALDAS VISRAM AND COMPANY LIMITED: $3.3 million (57.3% of total imports)
ALTOVA HEALTHCARE LIMITED: $1.4 million (24.6% of total imports)
GOPALDAS VISRAM COMPANY LIMITED: $1.0 million (18.1% of total imports)

This concentration indicates a strategic choice to maintain strong relationships with select suppliers, potentially ensuring consistent product quality and supply reliability. However, such dependency also poses risks, including supply chain disruptions if any of these suppliers face operational challenges. The shipment data, with 214 shipments from GOPALDAS VISRAM AND COMPANY LIMITED, 234 from ALTOVA HEALTHCARE LIMITED, and 85 from GOPALDAS VISRAM COMPANY LIMITED, suggests a stable and ongoing partnership with these suppliers.

2Supply Chain Resilience

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) is the primary regulatory body overseeing the importation of pharmaceutical products. The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the legal framework governing the importation of drugs, ensuring they meet standards for safety, efficacy, and quality. Imported drugs must comply with FDA regulations, including proper labeling, manufacturing practices, and approval processes. The FDA's guidance on human drug imports outlines the requirements for imported drugs, emphasizing the need for compliance with U.S. standards.

2Import Licensing & GMP

Importers of pharmaceutical products into the U.S. must ensure that their foreign suppliers are registered with the FDA and that their products are listed appropriately. Good Manufacturing Practice (GMP) certification is essential, with the FDA recognizing certifications from reputable authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications attest to the quality and safety of the manufacturing processes. Additionally, importers must obtain wholesale distribution authorization, which involves compliance with state-specific regulations and may require licensure or permits.

Dynarex Corporation — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Dynarex's focus on importing Vitamins & Supplements and Corticosteroids aligns with significant market demand in the U.S. These therapeutic areas address prevalent health concerns, such as nutritional deficiencies and inflammatory conditions, making them essential components of healthcare regimens. By sourcing these products from India, Dynarex can offer cost-effective solutions without compromising on quality, thereby meeting the needs of a diverse consumer base.

2Sourcing Profile

Dynarex's sourcing strategy emphasizes the procurement of generic pharmaceutical formulations, particularly in the Vitamins & Supplements and Corticosteroids categories. This approach allows the company to provide affordable alternatives to brand-name drugs, catering to cost-conscious consumers and healthcare providers. India's established pharmaceutical manufacturing industry, with its adherence to international quality standards, makes it a strategic partner for Dynarex in this endeavor.

3Market Positioning

With its diverse product mix, including imported pharmaceutical formulations, Dynarex serves multiple segments of the U.S. market. The company's offerings are suitable for retail pharmacies, hospitals, government tenders, and wholesale distribution, providing a comprehensive solution to various healthcare needs. This broad market positioning enables Dynarex to leverage economies of scale and strengthen its presence across different healthcare sectors.

Seller's Guide — How to Become a Supplier to Dynarex Corporation

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Dynarex, especially if they can offer high-quality pharmaceutical formulations that meet U.S. regulatory standards. Gaps in Dynarex's current sourcing may exist in specific product formulations or therapeutic areas not currently covered. New suppliers can explore these niches to establish a foothold in the U.S. market. Building strong relationships with Dynarex and demonstrating consistent product quality will be key to success.

2Requirements & Qualifications

Indian exporters aiming to supply Dynarex and the broader U.S. market must obtain GMP certifications recognized by the FDA, such as EU GMP, WHO GMP, or PIC/S. Additionally, they must ensure that their products comply with FDA labeling requirements, including English language labeling and accurate product information. Establishing a robust quality management system and maintaining consistent product quality are essential to meet these standards.

3How to Approach

Frequently Asked Questions — Dynarex Corporation

What products does Dynarex Corporation import from India?

Dynarex Corporation imports 2 pharmaceutical products across 2 categories. Top imports: Zinc ($2.0M), Hydrocortisone ($806.4K).

Who supplies pharmaceuticals to Dynarex Corporation from India?

Dynarex Corporation sources from 3 verified Indian suppliers. The primary supplier is Gopaldas Visram And Company Limited (57.3% of imports, $3.3M).

What is Dynarex Corporation's total pharmaceutical import value?

Dynarex Corporation's total pharmaceutical import value from India is $2.8M, based on 227 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Dynarex Corporation focus on?

Dynarex Corporation imports across 2 categories. The largest: Vitamins & Supplements (71.1%), Corticosteroids (28.9%).

Get Full Dynarex Corporation Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.